The SAME-TT₂R₂ score predicts the quality of anticoagulation control in patients with acute VTE

Summary

The SAMe-TT2R2 score has recently been proposed to predict the quality of vitamin K antagonist (VKA) anticoagulation control in patients with atrial fibrillation. We aimed at investigating whether the score is effective also in patients with venous thromboembolism (VTE). Patients included in the START-Register because started VKA therapy for a recent VTE episode and with > 3 months follow-up were analyzed. The score was calculated using the baseline patient’s characteristics present in the electronic database of the registry, where all INR results were also available and analysed to calculate the time in therapeutic range (TTR). A total of 1308 patients (53.4 % female, median age 68 years) were analysed. During 998 patient-years followup, the median TTR was 63 %. The maximum score in the patients was 4, with 70 % of them having 0–1. INR controls within range (2.0–3.0) were significantly less prevalent in patients with score ≥ 2 vs 0–1 score (58.5 ± 20 % vs 61.5 ± 19 %, respectively, p = 0.046). Patients with score ≥ 2 vs 0–1 had a highly significant lower TTR during the first 3 months of therapy (53 ± 26 % and 61 ± 26 %, respectively; p=0.0001), difference mainly due to more time spent below 2.0 INR (38 ± 28 % vs 31.3 ± 26.7 %, respectively; p=0.0001). In conclusion, the study proved, for the first time, that the SAMe-TT₂R₂ score is useful to predict among VTE patients those who will have good (score 0–1) or less good (score ≥ 2) VKA anticoagulation control. The score can help decision-making in everyday clinical practice, especially when choosing between VKA and non-vitamin K antagonists direct anticoagulants.

Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.

Keywords

Anticoagulants - quality control - warfarin - SAMe-TT2R2 score

^* The START-Register Participants who contributed to this study are listed in the Appendix.

• References

• 1 Wan Y, Heneghan C, Perera R. et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 01: 84-91.
• 2 De Caterina R, Husted S, Wallentin L. et al. Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
• 3 Gallego P, Lip GY, Lane DA. Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace 2013; 15: 773-774.
• 4 Jones M, McEwan P, Morgan CL. et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
• 5 Palareti G, Manotti C, DA A. et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-1443.
• 6 White HD, Gruber M, Feyzi J. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control - Results from SPORTIF III and IV. Arch Intern Med 2007; 167: 239-245.
• 7 Barrios V, Escobar C, Prieto L. et al. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centres in Spain: The PAULA Study. Rev Esp Cardiol 2015; 68: 769-776.
• 8 Cinza-Sanjurjo S, Rey-Aldana D, Gestal-Pereira E. et al. Assessment of Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Primary Health Care in Galicia, Spain: ANFAGAL Study. Rev Esp Cardiol 2015; 68: 753-760.
• 9 Boutitie F, Pinede L, Schulman S. et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. Br Med J 2011; 342: d3036.
• 10 Mearns ES, Kohn CG, Song JS. et al. Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. Thromb Res 2014; 134: 310-319.
• 11 Kooistra HA, Gebel M, Sahin K. et al. Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies. Thromb Haemost 2015; 114: 1136-1143.
• 12 Lopez-Sendon J, Merino JL. Poor Anticoagulation Control in Atrial Fibrillation: How Much Longer?. Rev Esp Cardiol 2015; 68: 740-742.
• 13 Azoulay L, Dell’Aniello S, Simon TA. et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881-1887.
• 14 Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-1563.
• 15 Gallego P, Roldan V, Marin F. et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
• 16 Poli D, Antonucci E, Testa S. et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014; 09: 443-447.
• 17 Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S. et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a realworld cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace 2015; 17: 711-717.
• 18 Fauchier L, Angoulvant D, Lip GY. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015; 17: 671-673.
• 19 Ruiz-Ortiz M, Bertomeu V, Cequier A. et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost 2015; 114: 695-701.
• 20 Antonucci E, Poli D, Tosetto A. et al. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One 2015; 10: e0124719.
• 21 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 22 Buller HR, Cohen AT, Davidson B. et al. Idraparinux vs standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
• 23 Rosendaal FR, Cannegieter SC, Vandermeer FJM. et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-237.
• 24 Skov J, Bladbjerg EM, Bor MV. et al. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014; 145: 187-188.
• 25 Lip GY, Haguenoer K, Saint-Etienne C. et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
• 26 Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2. Eur Heart J - Cardiovasc Pharmacol. 2015 Epub ahead of print.
• 27 Erkens PM, ten Cate H, Buller HR. et al. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One 2012; 07: e42269.
• 28 Veeger NJGM, PiersmaWichers M, Tijssen JGP. et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128: 513-519.
• 29 Gallagher AM, de Vries F, Plumb JM. et al. Quality of INR control and outcomes following venous thromboembolism. Clin Appl Thromb Hemost 2012; 18: 370-378.
• 30 Gadisseur AP, Christiansen SC, Van DERMF J. et al. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. J Thromb Haemost 2007; 05: 931-936.
• 31 Palareti G, Legnani C, Cosmi B. et al. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for longterm recurrence. J Thromb Haemost 2005; 03: 955-961.